{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:33Z","timestamp":1790239413382,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81703623"],"award-info":[{"award-number":["81703623"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Foundation of Hunan","award":["2018JJ3719"],"award-info":[{"award-number":["2018JJ3719"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["320.6750.2020-04-14"],"award-info":[{"award-number":["320.6750.2020-04-14"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The association between Glutathione S-transferase Pi 1(<jats:italic toggle=\"yes\">GSTP1<\/jats:italic>) genetic polymorphism (rs1695, 313A&gt;G) and cyclophosphamide-induced toxicities has been widely investigated in previous studies, however, the results were inconsistent. This study was performed to further elucidate the association.<\/jats:p>\n            <jats:p>A comprehensive search was conducted in PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wan Fang database up to January 5, 2020. Risk ratios (RRs) and 95% confidence intervals (95% CIs) were used to estimate the association between <jats:italic toggle=\"yes\">GSTP1<\/jats:italic> rs1695 polymorphism and cyclophosphamide-induced hemotoxicity, gastrointestinal toxicity, infection, and neurotoxicity.<\/jats:p>\n            <jats:p>A total of 13 studies were eventually included. Compared with the <jats:italic toggle=\"yes\">GSTP1<\/jats:italic> rs1695 AA genotype carriers, patients with AG and GG genotypes had an increased risk of cyclophosphamide-induced gastrointestinal toxicity (RR, 1.61; 95% CI, 1.18\u20132.19; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.003) and infection (RR, 1.57; 95% CI, 1.00\u20132.48; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.05) in the overall population. In the subgroup analyses, there were significant associations between <jats:italic toggle=\"yes\">GSTP1<\/jats:italic> rs1695 polymorphism and the risk of cyclophosphamide-induced myelosuppression (RR, 2.10; 95% CI, 1.60\u20132.76; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001), gastrointestinal toxicity (RR, 1.77; 95%CI, 1.25\u20132.53; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001), and infection (RR, 2.01; 95% CI, 1.14\u20133.54; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.02) in systemic lupus erythematosus (SLE) or lupus nephritis syndrome patients, but not in cancer patients.<\/jats:p>\n            <jats:p>Our results confirmed an essential role for the <jats:italic toggle=\"yes\">GSTP1<\/jats:italic> rs1695 polymorphism in the prediction of cyclophosphamide-induced myelosuppression, gastrointestinal toxicity, and infection in SLE or lupus nephritis syndrome patients. More studies are necessary to validate our findings in the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024423","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T22:06:22Z","timestamp":1615932382000},"page":"e24423","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Evaluating the role of GSTP1 genetic polymorphism (rs1695, 313A&gt;G) as a predictor in cyclophosphamide-induced toxicities"],"prefix":"10.1097","volume":"100","author":[{"given":"Jin-Yu","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Lan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ying","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-4205","authenticated-orcid":false,"given":"Jian-Quan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","article-title":"Does cyclophosphamide still play a role in glomerular diseases?","volume":"17","author":"Ponticelli","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.rbr.2016.04.009","article-title":"Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review","volume":"57","author":"Teles","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/bcp.14031","article-title":"The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes","volume":"85","author":"Helsby","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2015.12.007","article-title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma","volume":"55","author":"Veal","year":"2016","journal-title":"Eur J Cancer"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/jhg.2009.79","article-title":"Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients","volume":"54","author":"Low","year":"2009","journal-title":"J Hum Genet"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12291-018-0787-1","article-title":"Glutathione S-Transferase P1 313 (A > G) Ile105Val polymorphism contributes to cancer susceptibility in indian population: a meta-analysis of 39 case-control studies","volume":"35","author":"Mandal","year":"2020","journal-title":"Indian J Clin Biochem"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12282-014-0547-x","article-title":"Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer","volume":"23","author":"Sugishita","year":"2016","journal-title":"Breast Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","article-title":"Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus","volume":"62","author":"Zhong","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-10-0281","article-title":"Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer","volume":"16","author":"Yao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1007\/s13277-015-3211-y","article-title":"Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide- epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients","volume":"36","author":"Islam","year":"2015","journal-title":"Tumor Biol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cancergencyto.2009.12.004","article-title":"Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma","volume":"198","author":"Cho","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12885-017-3483-2","article-title":"Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy","volume":"17","author":"Ludovini","year":"2017","journal-title":"BMC Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jnci.2017.07.002","article-title":"Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia","volume":"29","author":"Abo-Bakr","year":"2017","journal-title":"J Egypt Natl Canc Inst"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.13181\/mji.v25i2.1308","article-title":"The influence of glutathion S-transferase P-1 polymorphism A313G rs1695 on the susceptibility to cyclophosphamide hematologic toxicity in Indonesian patients","volume":"25","author":"Hasni","year":"2016","journal-title":"Med J Indonesia"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s40267-019-00631-x","article-title":"Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients","volume":"35","author":"Thu","year":"2019","journal-title":"Drugs Ther Perspect"},{"key":"R19-20250504","first-page":"741","article-title":"Correlation between polymorphisms of GSTM1, GSTT1 and GSTP1 (rs1695) on hematologic toxicities with anthracycline\/paclitaxel-based chemotherapy in breast cancer","volume":"42","author":"Liu","year":"2014","journal-title":"Tianjin Med J"},{"key":"R20-20250504","first-page":"99","article-title":"Relation of glutathione S -transferase genotype with the adverse drug reaction of cyclophosphamide in nephrotic syndrome patients","volume":"29","author":"Wei","year":"2009","journal-title":"Chin Hosp Pharm J"},{"key":"R21-20250504","first-page":"980","article-title":"Study on the relationship of GSTP1(rs1695) genetic polymorphism with hematological toxicity of autologous hematopoietic stem cell transplantation patients","volume":"29","author":"Zhang","year":"2018","journal-title":"J China Pharm"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"e5151","DOI":"10.1097\/MD.0000000000005151","article-title":"Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients A hospital-based observational study","volume":"95","author":"Tsuji","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.09.034","article-title":"Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study","volume":"105","author":"Zambetti","year":"2018","journal-title":"Eur J Cancer"},{"key":"R24-20250504","first-page":"199","article-title":"Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer","volume":"124","author":"Zhang","year":"2011","journal-title":"Chin Med J (Engl )"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2005.08.035","article-title":"Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival","volume":"100","author":"Beeghly","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e67589","DOI":"10.1371\/journal.pone.0067589","article-title":"The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China","volume":"8","author":"Ge","year":"2013","journal-title":"PLoS One"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.fct.2017.03.020","article-title":"Inhibition of JNK by pi class of glutathione S-transferase through PKA\/CREB pathway is associated with carnosic acid protection against 6-hydroxydopamine-induced apoptosis","volume":"103","author":"Lin","year":"2017","journal-title":"Food Chem Toxicol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s12035-012-8266-9","article-title":"Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway","volume":"45","author":"Castro-Caldas","year":"2012","journal-title":"Mol Neurobiol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"e0144234","DOI":"10.1371\/journal.pone.0144234","article-title":"Association between Thiopurine S-Methyltransferase polymorphisms and azathioprine-induced adverse drug reactions in patients with autoimmune diseases: a meta-analysis","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40291-013-0045-4","article-title":"Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach","volume":"17","author":"Tulsyan","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.3816\/CBC.2003.s.012","article-title":"Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?","volume":"4","author":"Kaklamani","year":"2003","journal-title":"Clin Breast Cancer"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2011.12.012","article-title":"Epirubicin: is it like doxorubicin in breast cancer? A clinical review","volume":"21","author":"Khasraw","year":"2012","journal-title":"Breast"},{"key":"R33-20250504","first-page":"21572","article-title":"Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis","volume":"8","author":"Sun","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2217\/14622416.7.4.613","article-title":"The role of genetic variability in drug metabolism pathways in breast cancer prognosis","volume":"7","author":"Choi","year":"2006","journal-title":"Pharmacogenomics"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine-induced peripheral neuropathy in children with cancer: a systematic review","volume":"114","author":"van de Velde","year":"2017","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:28:58Z","timestamp":1746340138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024423","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"2020-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}